Uganda National Drug Authority (NDA) Regulatory Framework

The National Drug Authority (NDA) of Uganda serves as the principal regulatory body overseeing the safety, efficacy, and quality of drugs and health-related products in the country. Established under the National Drug Policy and Authority Act, Cap 206, the NDA's mandate encompasses the control of importation, exportation, manufacture, distribution, and sale of pharmaceuticals. Recent legislative reforms, notably the National Drug and Health Products Authority Bill, 2025, have significantly expanded its scope to include a broader range of health products and introduced more stringent penalties for non-compliance. This article explores the NDA's foundational legal framework, its evolving functions, and the critical enforcement and compliance challenges it addresses, providing practitioners with a comprehensive overview of Uganda's drug regulatory landscape.

Uganda's pharmaceutical sector is governed by a robust, albeit evolving, regulatory framework designed to safeguard public health. At the heart of this framework is the National Drug Authority (NDA), a statutory body established to ensure that all drugs and health-related products available to the Ugandan populace are safe, efficacious, and of acceptable quality. The NDA's role is critical in a country grappling with challenges such as counterfeit medicines, unregulated drug outlets, and the imperative to promote local pharmaceutical production and innovation.

This article provides a detailed profile of the National Drug Authority, outlining its legal genesis, core functions, and the significant legislative advancements that have recently reshaped its mandate. For legal practitioners, understanding the NDA's powers, responsibilities, and the intricacies of its regulatory oversight is paramount for advising clients in the pharmaceutical industry, healthcare providers, and other stakeholders navigating Uganda's drug control landscape. The recent enactment of the National Drug and Health Products Authority Bill, 2025, marks a pivotal moment, introducing expanded regulatory scope and enhanced enforcement mechanisms that demand close attention from the legal community.

By examining the statutory underpinnings, operational activities, and contemporary challenges faced by the NDA, this article aims to equip legal professionals with the necessary insights to ensure compliance, mitigate risks, and effectively engage with the regulatory authority in Uganda's dynamic health sector.

The National Drug Authority was established in 1993 by the National Drug Policy and Authority Statute, which was subsequently consolidated into the National Drug Policy and Authority Act, Cap 206 of the Laws of Uganda. This foundational legislation set out to establish a national drug policy and create the Authority with the primary objective of ensuring the continuous availability of essential, efficacious, and cost-effective drugs to the entire population of Uganda. The Act provided the NDA with the mandate to deal with the development and regulation of pharmacies and drugs, control their importation, exportation, and sale, and ensure the quality of drugs supplied in the country.

Over the years, the regulatory landscape has evolved, necessitating updates to the original framework. The National Drug Policy and Authority Act, Cap 206, also provided for various subsidiary regulations, including the National Drug Policy and Authority (Conduct of Clinical Trials) Regulations, 2014; the National Drug Policy and Authority (Importation and Exportation of Drugs) Regulations, 2014; the National Drug Policy and Authority (Licensing) Regulations, 2014; and the National Drug Policy and Authority (Pharmacovigilance) Regulations, 2014. These regulations provided detailed procedures for specific aspects of drug control, from clinical trials to post-market surveillance. However, the rapid advancements in health products and persistent regulatory challenges highlighted the need for a more comprehensive and modern legal instrument.

In a significant development, the Parliament of Uganda passed the National Drug and Health Products Authority Bill, 2025, on March 26, 2026. This new legislation is poised to repeal and replace the 1993 Act, establishing the National Drug and Health Products Authority as the central body responsible for regulating, controlling, and supervising a much broader spectrum of health products. The expanded mandate now explicitly includes vaccines, diagnostics, biologicals, medical devices, cosmetics, public health products, and nutritional supplements, reflecting a comprehensive approach to health product regulation.

The NDA's operational framework under the National Drug Policy and Authority Act, Cap 206, has historically focused on core functions such as licensing and inspecting pharmaceutical manufacturers, reviewing and approving product registrations, enforcing Good Manufacturing Practices (GMP), and regulating labeling and advertising. The Authority conducts rigorous inspections of both domestic and foreign manufacturing sites to ensure compliance with quality, safety, and efficacy standards. Post-market surveillance and pharmacovigilance activities are integral to its mandate, ensuring that products on the market remain safe and effective.

However, the NDA has faced persistent challenges, including the proliferation of substandard and counterfeit drugs, illegal drug outlets, and the need for enhanced enforcement capacity. Enforcement actions frequently involve closing unlicensed premises, impounding illicit medicines, and prosecuting individuals found operating without valid licenses or in possession of government drugs. These operations underscore the NDA's commitment to protecting public health, but also highlight the scale of non-compliance within the sector.

The recently passed National Drug and Health Products Authority Bill, 2025, introduces significant reforms aimed at addressing these challenges. It not only broadens the regulatory scope but also imposes stringent penalties for non-compliance, including substantial fines and lengthy imprisonment for manufacturing or distributing drugs without a license, illegal importation, and unapproved advertising. A notable provision allows for the controlled use of unapproved drugs in life-threatening situations, such as clinical trials or compassionate use in emergencies, providing a legal pathway for access under strict conditions. Furthermore, the new law introduces requirements for unique identifiers to enhance traceability and combat counterfeits, and empowers regulators to enforce minimum distance requirements between pharmacies to promote equitable access.

While the NDA's mandate is extensive, it is important for practitioners to note that the regulation of pharmacy practice and premises licensing falls under the purview of the Pharmacy Council of Uganda and the Allied Health Professionals Council, not the NDA. This distinction is crucial for understanding the specific regulatory body responsible for different aspects of pharmaceutical oversight. The NDA also collaborates with other agencies like the Uganda National Bureau of Standards (UNBS) and the Ministry of Health, and participates in regional harmonization efforts such as the EAC Medicines Regulatory Harmonisation (EAC-MRH) program, reflecting a commitment to international standards and regional cooperation.

The National Drug Authority stands as a critical pillar in Uganda's public health infrastructure, with a mandate to ensure the safety, efficacy, and quality of health products. The recent legislative overhaul through the National Drug and Health Products Authority Bill, 2025, signifies a proactive step by the Ugandan government to modernize its regulatory framework, expand its reach to a wider array of health products, and strengthen enforcement capabilities. This new era of regulation will undoubtedly lead to increased scrutiny and more rigorous compliance requirements across the pharmaceutical and health products industries.

For legal practitioners, it is imperative to thoroughly understand the expanded scope of the NDA's authority, the new penalties for non-compliance, and the specific provisions related to product registration, advertising, and post-market surveillance. Clients involved in the manufacture, importation, distribution, or sale of any health-related product in Uganda must review their operations to ensure full alignment with the updated legal framework. Staying abreast of the NDA's enforcement trends, guidance documents, and ongoing initiatives, such as the Innovations & Research Desk and efforts against antimicrobial resistance, will be crucial for effective legal counsel and strategic business planning in this increasingly regulated sector.